{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T10:11:49Z","timestamp":1790244709666,"version":"4.1.0"},"reference-count":19,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"name":"Bayer Healthcare and BMS\/Pfizer"},{"name":"Astra-Zeneca"},{"name":"Bayer Healthcare, BMS\/Pfizer, Novartis, and Sanofi"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,11,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Aims<\/jats:title>\n                  <jats:p>The objective was to assess the association between angiotensin-converting enzyme inhibitors (ACEI) or angiotensin receptor blockers (ARB) prescription at discharge in patients hospitalized for symptomatic lower extremity artery disease (LEAD) and 1-year mortality.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods and results<\/jats:title>\n                  <jats:p>The COPART registry is a multicentre, prospective, observational, cohort study which includes consecutive patients hospitalized for symptomatic LEAD in four French academic centres. All-cause mortality during a 1-year follow-up after hospital discharge was compared between patients with ARB, patients with ACEI and patients without ARB or ACEI. Analyses were performed using Cox models. As a sensitivity analysis, a propensity score (PS)-matching analysis was carried out. Among 1981 patients, 421 had ARB (21.3%), 766 ACEI (38.7%), and 794 no ACEI\/ARB (40.1%) at discharge. During the 1-year follow-up, incidence rates for mortality were 12.6\/100 person-years [95% confidence interval (CI) 9.7\u201316.1] for patients with ARB, 15.8\/100 person-years (95% CI 13.4\u201318.6) for patients with ACEI and 19.8\/100 person-years for patients without ACEI\/ARB (95% CI 17.2\u201322.8). In a multivariate Cox model, ARB at discharge was associated with decreased mortality compared with no ACEI\/ARB, hazard ratio (HR) 0.68 (95% CI 0.49\u20130.95), and with ACEI, HR 0.69 (95% CI 0.49\u20130.97). These results are consistent with those obtained by the Cox analyses in the PS-matched sample: HR 0.68 (95% CI 0.47\u20130.98) for patients with ARB compared with no ARB.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Angiotensin receptor blockers at discharge after hospitalization for symptomatic LEAD is associated with a better survival compared with ACEI or no ACEI\/ARB.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ehjcvp\/pvaa026","type":"journal-article","created":{"date-parts":[[2020,4,3]],"date-time":"2020-04-03T11:09:41Z","timestamp":1585912181000},"page":"463-474","source":"Crossref","is-referenced-by-count":5,"title":["Impact of angiotensin receptor blockers on mortality after hospitalization for symptomatic lower extremity artery disease"],"prefix":"10.1093","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3101-3889","authenticated-orcid":false,"given":"Fran\u00e7ois-Xavier","family":"Lap\u00e9bie","sequence":"first","affiliation":[{"name":"Department of Vascular Medicine, Toulouse University Hospital, Toulouse, France"},{"name":"UMR 1027 INSERM, Toulouse III \u2013 Paul Sabatier University, 37 all\u00e9es Jules Guesde, 31000 Toulouse, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Bura-Rivi\u00e8re","sequence":"additional","affiliation":[{"name":"Department of Vascular Medicine, Toulouse University Hospital, Toulouse, France"},{"name":"UMR 1031 INSERM, StromaLab, Toulouse III \u2013 Paul Sabatier University, 4 bis avenue Hubert Curien, 31100 Toulouse, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Lacroix","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular and Thoracic Surgery \u2013 Vascular Medicine, Limoges University hospital, Limoges, France"},{"name":"UMR 1094 INSERM, Limoges University, 2 rue du Dr Marcland, 87000 Limoges, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jo\u00ebl","family":"Constans","sequence":"additional","affiliation":[{"name":"Department of Vascular Medicine, Bordeaux, Bordeaux University Hospital, France"},{"name":"Bordeaux University School of Medicine, 146 rue Leo Saignat, 33000 Bordeaux, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carine","family":"Boulon","sequence":"additional","affiliation":[{"name":"Department of Vascular Medicine, Bordeaux, Bordeaux University Hospital, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuel","family":"Messas","sequence":"additional","affiliation":[{"name":"Department of Vascular Medicine, Assistance Publique \u2013 H\u00f4pitaux de Paris, Paris, France"},{"name":"UMR 970 INSERM, Paris Descartes University, 56 rue Leblanc, 75015 Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor","family":"Aboyans","sequence":"additional","affiliation":[{"name":"UMR 1094 INSERM, Limoges University, 2 rue du Dr Marcland, 87000 Limoges, France"},{"name":"Department of Cardiology, Limoges University Hospital, Limoges, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean","family":"Ferri\u00e8res","sequence":"additional","affiliation":[{"name":"UMR 1027 INSERM, Toulouse III \u2013 Paul Sabatier University, 37 all\u00e9es Jules Guesde, 31000 Toulouse, France"},{"name":"Department of Epidemiology, Toulouse University Hospital, Toulouse, France"},{"name":"Federation of Cardiology, Toulouse University Hospital, 1 avenue du Pr Jean Poulh\u00e8s, 31400 Toulouse, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanina","family":"Bongard","sequence":"additional","affiliation":[{"name":"UMR 1027 INSERM, Toulouse III \u2013 Paul Sabatier University, 37 all\u00e9es Jules Guesde, 31000 Toulouse, France"},{"name":"Department of Epidemiology, Toulouse University Hospital, Toulouse, France"},{"name":"Federation of Cardiology, Toulouse University Hospital, 1 avenue du Pr Jean Poulh\u00e8s, 31400 Toulouse, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2020,5,1]]},"reference":[{"key":"2021110402482967100_pvaa026-B1","doi-asserted-by":"crossref","first-page":"e1020","DOI":"10.1016\/S2214-109X(19)30255-4","article-title":"Global, regional, and national prevalence and risk factors for peripheral artery disease in 2015: an updated systematic review and analysis","volume":"7","author":"Song","year":"2019","journal-title":"Lancet Glob Health"},{"key":"2021110402482967100_pvaa026-B2","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.ejvs.2015.10.022","article-title":"The risk of disease progression in peripheral arterial disease is higher than expected: a meta-analysis of mortality and disease progression in peripheral arterial disease","volume":"51","author":"Sigvant","year":"2016","journal-title":"Eur J Vasc Endovasc Surg"},{"key":"2021110402482967100_pvaa026-B3","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1056\/NEJM200001203420301","article-title":"Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients","volume":"342","author":"Yusuf","year":"2000","journal-title":"N Engl J Med"},{"key":"2021110402482967100_pvaa026-B4","first-page":"e686","article-title":"2016 AHA\/ACC guideline on the management of patients with lower extremity peripheral artery disease: executive summary: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"135","author":"Gerhard-Herman","year":"2017","journal-title":"Circulation"},{"key":"2021110402482967100_pvaa026-B5","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1093\/eurheartj\/ehx095","article-title":"2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS): document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteries Endorsed by: the European Stroke Organization (ESO) The Task Force for the Diagnosis and Treatment of Peripheral Arterial Diseases of the European Society of Cardiology (ESC) and of the European Society for Vascular Surgery (ESVS","volume":"39","author":"Aboyans","year":"2018","journal-title":"Eur Heart J"},{"key":"2021110402482967100_pvaa026-B6","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.mayocp.2015.10.019","article-title":"Angiotensin-converting enzyme inhibitors or angiotensin receptor blockers in patients without heart failure? Insights from 254,301 patients from randomized trials","volume":"91","author":"Bangalore","year":"2016","journal-title":"Mayo Clin Proc"},{"key":"2021110402482967100_pvaa026-B7","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.atherosclerosis.2016.08.001","article-title":"Angiotensin converting enzyme inhibitors and walking distance: have we walked the whole distance?","volume":"252","author":"Vlachopoulos","year":"2016","journal-title":"Atherosclerosis"},{"key":"2021110402482967100_pvaa026-B8","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/j.ejvs.2010.02.009","article-title":"Characteristics and outcome of patients hospitalised for lower extremity peripheral artery disease in France: the COPART Registry","volume":"39","author":"Cambou","year":"2010","journal-title":"Eur J Vasc Endovasc Surg"},{"key":"2021110402482967100_pvaa026-B9","first-page":"1339","article-title":"Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in high vascular risk","volume":"103","author":"Potier","year":"2017","journal-title":"Heart Br Card Soc"},{"key":"2021110402482967100_pvaa026-B10","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1001\/jama.295.2.180","article-title":"International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis","volume":"295","author":"Bhatt","year":"2006","journal-title":"JAMA"},{"key":"2021110402482967100_pvaa026-B11","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1016\/j.mayocp.2016.04.020","article-title":"In reply: The different effects of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on mortality","volume":"91","author":"Bangalore","year":"2016","journal-title":"Mayo Clin Proc"},{"key":"2021110402482967100_pvaa026-B12","first-page":"CD009096","article-title":"Angiotensin converting enzyme (ACE) inhibitors versus angiotensin receptor blockers for primary hypertension","volume":"8","author":"Li","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"2021110402482967100_pvaa026-B13","doi-asserted-by":"crossref","first-page":"1952","DOI":"10.1056\/NEJMoa042274","article-title":"Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy","volume":"351","author":"Barnett","year":"2004","journal-title":"N Engl J Med"},{"key":"2021110402482967100_pvaa026-B14","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1056\/NEJMoa032292","article-title":"Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both","volume":"349","author":"Pfeffer","year":"2003","journal-title":"N Engl J Med"},{"key":"2021110402482967100_pvaa026-B15","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1016\/j.jacc.2018.01.058","article-title":"Angiotensin-converting enzyme inhibitors in hypertension: to use or not to use?","volume":"71","author":"Messerli","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"2021110402482967100_pvaa026-B16","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1177\/2047487313519344","article-title":"Peripheral artery disease is a coronary heart disease risk equivalent among both men and women: results from a nationwide study","volume":"22","author":"Subherwal","year":"2015","journal-title":"Eur J Prev Cardiol"},{"key":"2021110402482967100_pvaa026-B17","first-page":"1","article-title":"Telmisartan, ramipril, or both in patients at high risk for vascular events","volume":"358","author":"Investigators","year":"2008","journal-title":"N Engl J Med"},{"key":"2021110402482967100_pvaa026-B18","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1016\/j.avsg.2011.12.001","article-title":"Role of the renin-angiotensin system in the pathogenesis of intimal hyperplasia: therapeutic potential for prevention of vein graft failure?","volume":"26","author":"Osgood","year":"2012","journal-title":"Ann Vasc Surg"},{"key":"2021110402482967100_pvaa026-B19","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.2337\/dc06-1551","article-title":"Impact of telmisartan versus ramipril on renal endothelial function in patients with hypertension and type 2 diabetes","volume":"30","author":"Schmieder","year":"2007","journal-title":"Diabetes Care"}],"container-title":["European Heart Journal - Cardiovascular Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ehjcvp\/advance-article-pdf\/doi\/10.1093\/ehjcvp\/pvaa026\/33031175\/pvaa026.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/ehjcvp\/article-pdf\/7\/6\/463\/41072934\/pvaa026.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/ehjcvp\/article-pdf\/7\/6\/463\/41072934\/pvaa026.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,4]],"date-time":"2021-11-04T02:49:21Z","timestamp":1635994161000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ehjcvp\/article\/7\/6\/463\/5818488"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,1]]},"references-count":19,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2020,5,1]]},"published-print":{"date-parts":[[2021,11,3]]}},"URL":"https:\/\/doi.org\/10.1093\/ehjcvp\/pvaa026","relation":{},"ISSN":["2055-6837","2055-6845"],"issn-type":[{"value":"2055-6837","type":"print"},{"value":"2055-6845","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,11]]},"published":{"date-parts":[[2020,5,1]]}}}